Myriad Genetics, Inc. (LON:0K3W)
5.31
+0.07 (1.34%)
Feb 5, 2026, 3:10 PM GMT
Myriad Genetics Revenue
Myriad Genetics had revenue of $205.70M USD in the quarter ending September 30, 2025, a decrease of -3.56%. This brings the company's revenue in the last twelve months to $825.30M, up 0.21% year-over-year. In the year 2024, Myriad Genetics had annual revenue of $837.60M with 11.21% growth.
Revenue (ttm)
$825.30M
Revenue Growth
+0.21%
P/S Ratio
0.59
Revenue / Employee
$305.67K
Employees
2,700
Market Cap
361.79M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 837.60M | 84.40M | 11.21% |
| Dec 31, 2023 | 753.20M | 74.80M | 11.03% |
| Dec 31, 2022 | 678.40M | -12.20M | -1.77% |
| Dec 31, 2021 | 690.60M | 133.50M | 23.96% |
| Dec 31, 2020 | 557.10M | -81.50M | -12.76% |
| Sep 30, 2020 | 638.60M | - | - |
| Jun 30, 2020 | 638.60M | - | - |
| Dec 31, 2019 | 638.60M | -212.50M | -24.97% |
| Jun 30, 2019 | 851.10M | - | - |
| Dec 31, 2018 | 851.10M | 107.40M | 14.44% |
| Jun 30, 2018 | 743.70M | - | - |
| Dec 31, 2017 | 743.70M | 15.00M | 2.06% |
| Jun 30, 2017 | 728.70M | -42.70M | -5.54% |
| Dec 31, 2016 | 771.40M | 30.90M | 4.17% |
| Jun 30, 2016 | 740.50M | -13.30M | -1.76% |
| Dec 31, 2015 | 753.80M | 30.70M | 4.25% |
| Jun 30, 2015 | 723.10M | -55.10M | -7.08% |
| Jun 30, 2014 | 778.20M | 165.00M | 26.91% |
| Jun 30, 2013 | 613.20M | 117.20M | 23.63% |
| Jun 30, 2012 | 496.01M | 93.92M | 23.36% |
| Jun 30, 2011 | 402.08M | 39.44M | 10.87% |
| Jun 30, 2010 | 362.65M | 36.12M | 11.06% |
| Jun 30, 2009 | 326.53M | 103.67M | 46.52% |
| Jun 30, 2008 | 222.86M | 77.57M | 53.39% |
| Jun 30, 2007 | 145.29M | 31.01M | 27.13% |
| Jun 30, 2006 | 114.28M | 31.87M | 38.68% |
| Jun 30, 2005 | 82.41M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.24B |
| GSK plc | 32.67B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Advanced Medical Solutions Group | 220.30M |
| Craneware | 150.11M |
| Integrated Diagnostics Holdings | 114.96M |
| Tristel | 46.46M |
Myriad Genetics News
- 9 days ago - Myriad Genetics Unveils Commercialization Roadmap For Precise MRD Assay - Nasdaq
- 9 days ago - Myriad Genetics (MYGN) Outlines Launch Plan for Precise MRD Assay - GuruFocus
- 21 days ago - Myriad Genetics Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
- 21 days ago - Myriad Genetics, Inc. (MYGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 21 days ago - Myriad Genetics, Inc. (MYGN) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow - Seeking Alpha
- 24 days ago - Myriad Genetics Reports Preliminary Q4 Revenue; Issues 2026 Guidance - Nasdaq
- 24 days ago - Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance - GlobeNewsWire
- 4 weeks ago - Myriad Genetics to Present at 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire